DK2885010T3 - Fremgangsmåder til behandling med tauopati - Google Patents
Fremgangsmåder til behandling med tauopati Download PDFInfo
- Publication number
- DK2885010T3 DK2885010T3 DK13830020.7T DK13830020T DK2885010T3 DK 2885010 T3 DK2885010 T3 DK 2885010T3 DK 13830020 T DK13830020 T DK 13830020T DK 2885010 T3 DK2885010 T3 DK 2885010T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- treating tauopathy
- tauopathy
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261683902P | 2012-08-16 | 2012-08-16 | |
US201361754085P | 2013-01-18 | 2013-01-18 | |
US201361781823P | 2013-03-14 | 2013-03-14 | |
US201361813797P | 2013-04-19 | 2013-04-19 | |
US201361833355P | 2013-06-10 | 2013-06-10 | |
PCT/US2013/055203 WO2014028777A2 (en) | 2012-08-16 | 2013-08-15 | Methods of treating a tauopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2885010T3 true DK2885010T3 (da) | 2020-02-03 |
Family
ID=50101612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13830020.7T DK2885010T3 (da) | 2012-08-16 | 2013-08-15 | Fremgangsmåder til behandling med tauopati |
Country Status (32)
Country | Link |
---|---|
US (6) | US9567395B2 (da) |
EP (2) | EP2885010B1 (da) |
JP (1) | JP6290212B2 (da) |
KR (1) | KR102076384B1 (da) |
CN (1) | CN104736185B (da) |
AU (1) | AU2013302540B2 (da) |
BR (1) | BR112015003326A2 (da) |
CA (1) | CA2882034C (da) |
CL (1) | CL2015000352A1 (da) |
CY (1) | CY1123515T1 (da) |
DK (1) | DK2885010T3 (da) |
EA (2) | EA035976B1 (da) |
ES (1) | ES2775192T3 (da) |
GB (1) | GB2507207A (da) |
HK (1) | HK1208175A1 (da) |
HR (1) | HRP20200036T1 (da) |
HU (1) | HUE048780T2 (da) |
IL (1) | IL237153B (da) |
LT (1) | LT2885010T (da) |
ME (1) | ME03667B (da) |
MX (1) | MX359817B (da) |
MY (1) | MY176838A (da) |
NZ (2) | NZ630542A (da) |
PE (1) | PE20150646A1 (da) |
PH (1) | PH12015500196A1 (da) |
PL (1) | PL2885010T3 (da) |
PT (1) | PT2885010T (da) |
RS (1) | RS60080B1 (da) |
SG (2) | SG11201500888SA (da) |
SI (1) | SI2885010T1 (da) |
TN (1) | TN2015000050A1 (da) |
WO (1) | WO2014028777A2 (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
EP3838921A3 (en) | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
HUE048780T2 (hu) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Tauopátia kezelésére szolgáló módszerek |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
EA039554B1 (ru) * | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
CA2931396C (en) * | 2013-11-27 | 2022-09-06 | Ipierian, Inc. | An anti-tau antibody for treating tauopothy |
JP6608827B2 (ja) | 2013-12-20 | 2019-11-20 | エフ.ホフマン−ラ ロシュ アーゲー | ヒト化抗タウ(pS422)抗体及び使用方法 |
CN105939722A (zh) * | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
AR100978A1 (es) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對tau之抗體及其用途 |
CN107466292B (zh) | 2015-03-16 | 2020-05-01 | 国家医疗保健研究所 | 新型1,4-双(3-氨基丙基)哌嗪衍生物及其用途 |
TWI790642B (zh) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
EP3307320A4 (en) * | 2015-06-12 | 2019-03-06 | C2N Diagnostics LLC | Stable formulations of humanized anti-tau antibodies |
JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
EP3744732A1 (en) | 2015-06-24 | 2020-12-02 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
SG10202010735PA (en) * | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
EA036821B1 (ru) | 2015-07-06 | 2020-12-23 | Юсб Биофарма Срл | Тау-связывающие антитела |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
US10358503B2 (en) * | 2015-08-13 | 2019-07-23 | New York University | Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
BR112018072394A2 (pt) | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem a tau |
EP3452508A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3022673A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
SG11201811015RA (en) | 2016-07-12 | 2019-01-30 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
EP3487524A4 (en) * | 2016-07-20 | 2020-03-25 | Anahit Ghochikyan | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
CN109562067A (zh) * | 2016-08-02 | 2019-04-02 | 库里尔克思股份有限公司 | 制备脂质体的方法 |
CA3032692A1 (en) * | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
TW202328181A (zh) * | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
MX2019009817A (es) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
MA48996A (fr) | 2017-03-28 | 2020-02-05 | Genentech Inc | Méthodes de traitement de maladies neurodégénératives |
IL270375B1 (en) | 2017-05-02 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize tau |
AU2017418317A1 (en) * | 2017-06-16 | 2019-12-05 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
CN111630064B (zh) | 2017-10-16 | 2023-06-27 | 卫材R&D管理有限公司 | 抗Tau抗体及其用途 |
CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院(血液学研究所) | 高效率血细胞重编程同时实现基因编辑的方法 |
JP7437376B2 (ja) * | 2018-07-19 | 2024-02-22 | ジェネンテック,インコーポレーテッド | マーカー分子に基づいて、アミロイド陽性認知症を罹患していると、または発症するリスクがあると個体を同定する方法、および関連する使用 |
JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
CN113508135A (zh) | 2018-10-29 | 2021-10-15 | 比奥根Ma公司 | 增强血脑屏障转运的人源化和稳定化的fc5变体 |
CA3118818A1 (en) * | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2020153940A1 (en) * | 2019-01-22 | 2020-07-30 | Clemson University | Anti-elastin antibodies and methods of use |
TW202100550A (zh) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | 識別tau之抗體 |
JP7181438B2 (ja) | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
CA3159311A1 (en) * | 2019-12-05 | 2021-06-10 | Axoltis Pharma | Peptide compositions and methods for treating tauopathies |
CN116249712A (zh) | 2020-04-15 | 2023-06-09 | 沃雅戈治疗公司 | Tau结合化合物 |
JP7554292B2 (ja) | 2020-06-25 | 2024-09-19 | メルク・シャープ・アンド・ドーム・エルエルシー | セリン413においてリン酸化されたタウを標的化する高親和性抗体 |
JP2023554382A (ja) | 2020-12-16 | 2023-12-27 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
KR20240049296A (ko) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | 타우 병증을 치료하는 방법 |
WO2023039107A2 (en) * | 2021-09-09 | 2023-03-16 | Alzpath, Inc. | Phospho-tau antibodies and methods of use |
WO2023081194A2 (en) * | 2021-11-03 | 2023-05-11 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
AU2414092A (en) | 1991-08-01 | 1993-03-02 | Paul H. Voorheis | Diagnostic method for alzheimer's disease |
US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
WO1993008302A1 (en) | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
JP2579202Y2 (ja) | 1992-04-10 | 1998-08-20 | 株式会社小松製作所 | 圧力補償弁を備えた操作弁 |
US5600392A (en) | 1992-11-25 | 1997-02-04 | Copal Company Limited | Position sensor |
EP0905253A3 (en) | 1992-12-03 | 2000-11-02 | Genzyme Corporation | Adenoviral vector deleted of all E4-ORF except ORF6 |
US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
ATE314482T1 (de) | 1993-10-25 | 2006-01-15 | Canji Inc | Rekombinante adenoviren-vektor und verfahren zur verwendung |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
WO1995017429A1 (en) | 1993-12-21 | 1995-06-29 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
US6121003A (en) | 1994-07-29 | 2000-09-19 | Innogentics N.V. | Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
WO1996019487A1 (fr) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Derives d'organobismuth et procede de production |
US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
US20040014142A1 (en) | 1998-07-03 | 2004-01-22 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
JP2003531570A (ja) | 1999-07-27 | 2003-10-28 | アブジェニックス インク. | 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物 |
ES2274869T3 (es) | 2000-01-24 | 2007-06-01 | Innogenetics N.V. | Diagnostico de tauopatias determinando la relacion tau/fosfotau. |
DE60141752D1 (de) | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
JP2004503747A (ja) | 2000-07-11 | 2004-02-05 | モレキュラー ジェリアトリクス コーポレイション | 結合物質の同定するための試薬と方法 |
WO2002045743A2 (en) * | 2000-12-09 | 2002-06-13 | Cambridge University Technical Services Limited | Hcv vaccines |
US7466180B2 (en) | 2000-12-12 | 2008-12-16 | Intel Corporation | Clock network |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
WO2002094191A2 (en) | 2001-05-23 | 2002-11-28 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
EP1425694A2 (en) | 2001-08-03 | 2004-06-09 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
DK1427709T3 (da) | 2001-09-21 | 2006-04-03 | Mitsubishi Pharma Corp | 3-substituerede 4-pyrimidonderivater |
WO2004001421A2 (en) | 2002-06-21 | 2003-12-31 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
CN100577803C (zh) | 2002-07-12 | 2010-01-06 | 阿克松神经科学研究和发展股份有限公司 | 表达阿耳茨海默氏tau蛋白的转基因动物 |
US7250551B2 (en) | 2002-07-24 | 2007-07-31 | President And Fellows Of Harvard College | Transgenic mice expressing inducible human p25 |
ES2352668T3 (es) | 2002-08-14 | 2011-02-22 | Mitsubishi Chemical Medience Corporation | Anticuerpo específico para una proteína tau del sistema nervioso central. |
EP1480041A1 (en) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
KR100835786B1 (ko) | 2003-07-08 | 2008-06-09 | 제넨테크, 인크. | Il-17a/f 이종 폴리펩티드 및 그의 치료 용도 |
US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
WO2005080986A1 (en) * | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
AU2005214091B2 (en) | 2004-02-24 | 2010-08-12 | Abbvie B.V. | Method for determining the risk of developing a neurological disease |
WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
AU2005251563B2 (en) * | 2004-06-09 | 2011-08-04 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
CN102603895B (zh) | 2004-06-18 | 2016-09-28 | Ambrx公司 | 新颖抗原结合多肽和其用途 |
CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
EP1772732A1 (en) | 2005-10-07 | 2007-04-11 | Innogenetics N.V. | Polymer replicated interdigitated electrode arrays for (bio)sensing applications |
US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
US20110143380A1 (en) | 2006-03-14 | 2011-06-16 | The Washington University | Alzheimer's disease biomarkers and methods of use |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US8729225B2 (en) | 2006-11-13 | 2014-05-20 | Intrexon Corporation | Glycogen synthase kinase heteropolyligand polypeptide |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
WO2009002607A1 (en) | 2007-05-01 | 2008-12-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
JP2010537200A (ja) | 2007-08-21 | 2010-12-02 | ワシントン ユニバーシティー | 改善されたアルツハイマー診断法 |
EP2185160B1 (en) | 2007-08-31 | 2019-02-13 | Neurimmune Holding AG | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
JP2010538611A (ja) | 2007-09-07 | 2010-12-16 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | タウタンパク質スクリーニングアッセイ |
US8506933B2 (en) | 2007-11-30 | 2013-08-13 | Msdx, Inc. | Methods of detecting a neurological condition via analysis of circulating phagocytes |
EP2313085A2 (en) | 2008-07-15 | 2011-04-27 | Novartis AG | Immunogenic amphipathic peptide compositions |
US9464122B2 (en) | 2008-08-20 | 2016-10-11 | Oligomerix, Inc. | Methods and compositions comprising tau oligomers |
WO2010021755A2 (en) | 2008-08-20 | 2010-02-25 | Oligomerix, Inc. | Tau protease compositions and methods |
CN103665170A (zh) | 2008-12-05 | 2014-03-26 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US8409584B2 (en) | 2009-05-05 | 2013-04-02 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
JP2012526990A (ja) | 2009-05-11 | 2012-11-01 | ネクサス・ディーエックス・インコーポレイテッド | 検体検出のための方法及び組成 |
JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
RU2518291C2 (ru) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Антигенные tau-пептиды и их применения |
JP6124591B2 (ja) | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
CA2778234C (en) | 2009-11-06 | 2018-05-15 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
WO2012045882A2 (en) | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
EP2627672B1 (en) | 2010-10-11 | 2018-08-01 | Biogen Idec International Neuroscience GmbH | Human anti-tau antibodies |
US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
EP4086338A1 (en) | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
SG10201703771WA (en) | 2011-09-19 | 2017-06-29 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
KR20160005380A (ko) | 2011-09-23 | 2016-01-15 | 에이씨 이뮨 에스.에이. | 백신 요법 |
MX354662B (es) | 2011-10-07 | 2018-03-14 | Ac Immune Sa | Anticuerpos fosfoespecificos que reconocen la tau. |
CA2853100A1 (en) | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
BR112014015323B1 (pt) | 2011-12-20 | 2022-09-27 | Janssen Biotech, Inc | Anticorpos anti-phf-tau, seu método de produção, polinucleotídeo isolado que codifica uma vh de anticorpo, e vetor |
AU2013243861A1 (en) | 2012-04-05 | 2014-10-23 | Ac Immune S.A. | Humanized Tau antibody |
EP3838921A3 (en) * | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
HUE048780T2 (hu) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Tauopátia kezelésére szolgáló módszerek |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US20160122421A1 (en) | 2013-06-10 | 2016-05-05 | Ipierian, Inc. | Methods of treating a tauopathy |
EA039554B1 (ru) * | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
CA2931396C (en) | 2013-11-27 | 2022-09-06 | Ipierian, Inc. | An anti-tau antibody for treating tauopothy |
CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
-
2013
- 2013-08-15 HU HUE13830020A patent/HUE048780T2/hu unknown
- 2013-08-15 PL PL13830020T patent/PL2885010T3/pl unknown
- 2013-08-15 MX MX2015001601A patent/MX359817B/es active IP Right Grant
- 2013-08-15 SI SI201331657T patent/SI2885010T1/sl unknown
- 2013-08-15 CA CA2882034A patent/CA2882034C/en active Active
- 2013-08-15 BR BR112015003326A patent/BR112015003326A2/pt not_active Application Discontinuation
- 2013-08-15 CN CN201380052696.6A patent/CN104736185B/zh not_active Expired - Fee Related
- 2013-08-15 JP JP2015527645A patent/JP6290212B2/ja active Active
- 2013-08-15 PT PT138300207T patent/PT2885010T/pt unknown
- 2013-08-15 PE PE2015000195A patent/PE20150646A1/es active IP Right Grant
- 2013-08-15 GB GB1322812.7A patent/GB2507207A/en not_active Withdrawn
- 2013-08-15 KR KR1020157006280A patent/KR102076384B1/ko active IP Right Grant
- 2013-08-15 RS RS20200245A patent/RS60080B1/sr unknown
- 2013-08-15 NZ NZ630542A patent/NZ630542A/en unknown
- 2013-08-15 EA EA201590388A patent/EA035976B1/ru unknown
- 2013-08-15 ME MEP-2020-44A patent/ME03667B/me unknown
- 2013-08-15 AU AU2013302540A patent/AU2013302540B2/en not_active Ceased
- 2013-08-15 SG SG11201500888SA patent/SG11201500888SA/en unknown
- 2013-08-15 NZ NZ730763A patent/NZ730763A/en not_active IP Right Cessation
- 2013-08-15 EP EP13830020.7A patent/EP2885010B1/en active Active
- 2013-08-15 WO PCT/US2013/055203 patent/WO2014028777A2/en active Application Filing
- 2013-08-15 EP EP19213625.7A patent/EP3685854A1/en not_active Withdrawn
- 2013-08-15 SG SG10201701181XA patent/SG10201701181XA/en unknown
- 2013-08-15 ES ES13830020T patent/ES2775192T3/es active Active
- 2013-08-15 DK DK13830020.7T patent/DK2885010T3/da active
- 2013-08-15 US US14/421,073 patent/US9567395B2/en active Active
- 2013-08-15 MY MYPI2015700487A patent/MY176838A/en unknown
- 2013-08-15 LT LTEP13830020.7T patent/LT2885010T/lt unknown
- 2013-11-27 US US14/092,539 patent/US8926974B2/en active Active
- 2013-12-12 US US14/104,717 patent/US20140099304A1/en not_active Abandoned
- 2013-12-12 US US14/104,706 patent/US20140099303A1/en not_active Abandoned
-
2014
- 2014-06-09 EA EA202193044A patent/EA202193044A2/ru unknown
-
2015
- 2015-01-29 PH PH12015500196A patent/PH12015500196A1/en unknown
- 2015-02-09 IL IL237153A patent/IL237153B/en active IP Right Grant
- 2015-02-13 TN TNP2015000050A patent/TN2015000050A1/fr unknown
- 2015-02-13 CL CL2015000352A patent/CL2015000352A1/es unknown
- 2015-09-10 HK HK15108856.9A patent/HK1208175A1/xx unknown
-
2017
- 2017-01-03 US US15/397,569 patent/US10040847B2/en active Active
-
2018
- 2018-07-16 US US16/036,309 patent/US20190169275A1/en not_active Abandoned
-
2020
- 2020-01-15 HR HRP20200036TT patent/HRP20200036T1/hr unknown
- 2020-03-31 CY CY20201100309T patent/CY1123515T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2885010T3 (da) | Fremgangsmåder til behandling med tauopati | |
DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
AR092198A1 (es) | Derivados de pirazolopirimidinas | |
DK2872497T4 (da) | Chromanyl-derivater til behandling af mitokondriel sygdom | |
BR112015001724A2 (pt) | métodos de tratamento de condições relacionadas a fgfr3 | |
SI3007726T1 (sl) | Metode zdravljenja tauopatije | |
DK2897611T3 (da) | Fremgangsmåder til behandling af hepatitis c | |
DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
DK2623661T3 (da) | Fremgangsmåde til vådbehandling af vasketøj | |
DK2892556T3 (da) | Sammensætninger og fremgangsmåder til behandling af sygdomme | |
BR112015002542A2 (pt) | método de caracterização de um objeto | |
DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
DK3486248T3 (da) | Forbedrede fremgangsmåder til acylering af maytansinol | |
ES1080381Y (es) | Fachada de medios | |
DK2820042T3 (da) | Igg-stimuleret remyelinisering af perifere nerver | |
FR2994506B1 (fr) | Adaptation de transistors | |
DK3473276T3 (da) | Teknikker til behandling af abscesser | |
FR2997080B1 (fr) | Inhibiteurs de neprilysine | |
FR2994008B1 (fr) | Methode de suivi de position 6d monocamera | |
DK2811993T3 (da) | Fremgangsmåder til behandling af fibrose | |
DK2908823T3 (da) | Fremgangsmåder til behandling af cancer | |
ES2390324B8 (es) | Juego de brocas | |
ES1076213Y (es) | Apero de labranza | |
FR2990827B1 (fr) | Tomme de chevre |